| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Bong-Soo Cha | Q61196432 |
| P2093 | author name string | Hye-Jin Yoon | |
| P2860 | cites work | Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis | Q22004166 |
| Role of AMP-activated protein kinase in mechanism of metformin action | Q22241898 | ||
| Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | Q22250883 | ||
| Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase | Q24309462 | ||
| Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis | Q24541529 | ||
| Mechanism of free fatty acid-induced insulin resistance in humans | Q24562106 | ||
| Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis | Q24625697 | ||
| Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice | Q24629441 | ||
| How mitochondria produce reactive oxygen species | Q24643882 | ||
| Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease | Q26825517 | ||
| Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges | Q27023893 | ||
| Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty | Q74432955 | ||
| A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis | Q78147915 | ||
| The role of MAPK in Kupffer cell toll-like receptor (TLR) 2-, TLR4-, and TLR9-mediated signaling following trauma-hemorrhage | Q79373033 | ||
| Statins and hepatic steatosis: perspectives from the Dallas Heart Study | Q80002035 | ||
| Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures | Q80119138 | ||
| The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial | Q39275836 | ||
| The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes | Q39451469 | ||
| Role of peroxisome proliferator-activated receptor gamma agonist in improving hepatic steatosis: Possible molecular mechanism | Q39604886 | ||
| MK615 attenuates Porphyromonas gingivalis lipopolysaccharide-induced pro-inflammatory cytokine release via MAPK inactivation in murine macrophage-like RAW264.7 cells | Q39808548 | ||
| Mechanism of HMGB1 release inhibition from RAW264.7 cells by oleanolic acid in Prunus mume Sieb. et Zucc | Q39862005 | ||
| Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study | Q39880419 | ||
| The natural history of nonalcoholic fatty liver: a follow-up study | Q40376691 | ||
| A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. | Q40464366 | ||
| Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. | Q41644055 | ||
| Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study | Q41739541 | ||
| Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. | Q42462295 | ||
| A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease | Q42654018 | ||
| Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis | Q42791977 | ||
| Obesity is associated with macrophage accumulation in adipose tissue | Q27860976 | ||
| Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice | Q28144106 | ||
| Toll-like receptors in the induction of the innate immune response | Q28144797 | ||
| One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study | Q28246121 | ||
| Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis | Q28290519 | ||
| Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality | Q28292632 | ||
| Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes | Q28575190 | ||
| The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin | Q28590162 | ||
| AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice | Q28591122 | ||
| SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver | Q29547646 | ||
| Steatohepatitis: a tale of two "hits"? | Q29547771 | ||
| Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults | Q29614911 | ||
| Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity | Q29614932 | ||
| Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity | Q29616103 | ||
| Molecular mediators of hepatic steatosis and liver injury | Q29616709 | ||
| The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association | Q29617157 | ||
| Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease | Q29619334 | ||
| Nonalcoholic fatty liver disease | Q29619354 | ||
| Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis | Q30448524 | ||
| Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis | Q33734679 | ||
| RBP4 activates antigen-presenting cells, leading to adipose tissue inflammation and systemic insulin resistance | Q33831780 | ||
| Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance | Q33941406 | ||
| Diacylglycerol-mediated insulin resistance | Q34109119 | ||
| Hepatic-Specific Disruption of SIRT6 in Mice Results in Fatty Liver Formation Due to Enhanced Glycolysis and Triglyceride Synthesis | Q34112535 | ||
| Toll-like receptor 3 ligand attenuates LPS-induced liver injury by down-regulation of toll-like receptor 4 expression on macrophages | Q34144580 | ||
| Adiponectin primes human monocytes into alternative anti-inflammatory M2 macrophages | Q34150591 | ||
| Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease | Q34357996 | ||
| Exercise, GLUT4, and skeletal muscle glucose uptake | Q34360751 | ||
| The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes | Q34370790 | ||
| Role of uncoupled and non-coupled oxidations in maintenance of safely low levels of oxygen and its one-electron reductants | Q34402690 | ||
| Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. | Q34415177 | ||
| Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. | Q34420472 | ||
| Hepatic steatosis and very low density lipoprotein secretion: the involvement of apolipoprotein E. | Q34459818 | ||
| PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis | Q34509964 | ||
| A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis | Q34585893 | ||
| Metformin--mode of action and clinical implications for diabetes and cancer | Q34658712 | ||
| High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial | Q42947254 | ||
| Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study | Q43152304 | ||
| Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial | Q43265559 | ||
| Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis | Q43269657 | ||
| Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities | Q43552270 | ||
| Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance | Q43687860 | ||
| Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study | Q43742730 | ||
| Metformin in non-alcoholic steatohepatitis. | Q43745120 | ||
| Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients | Q43840329 | ||
| Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes | Q43911547 | ||
| Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients | Q44018167 | ||
| Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. | Q44055110 | ||
| Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease | Q44080580 | ||
| Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus | Q44211004 | ||
| Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content | Q44328965 | ||
| Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. | Q44398229 | ||
| Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. | Q44527604 | ||
| Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone | Q44598595 | ||
| Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test | Q44627897 | ||
| Vitamin E treatment in pediatric obesity-related liver disease: a randomized study | Q44694111 | ||
| Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis | Q44696111 | ||
| Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients | Q44723054 | ||
| Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease | Q44726439 | ||
| A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis | Q44749300 | ||
| Differential requirement for c-Jun NH2-terminal kinase in TNFalpha- and Fas-mediated apoptosis in hepatocytes | Q44758408 | ||
| Metformin in the treatment of patients with non-alcoholic steatohepatitis | Q44778658 | ||
| Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity | Q44887140 | ||
| Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease | Q44934521 | ||
| Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis | Q45077756 | ||
| Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. | Q45265355 | ||
| Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms | Q45300618 | ||
| The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease | Q46328653 | ||
| Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis | Q46418008 | ||
| Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake | Q46473255 | ||
| Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease | Q46506089 | ||
| Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease | Q46685325 | ||
| Fatty liver and the metabolic syndrome among Shanghai adults | Q46841528 | ||
| Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome | Q46893987 | ||
| Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss | Q47417361 | ||
| Effect of weight reduction on hepatic abnormalities in overweight patients | Q47440169 | ||
| Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. | Q51500156 | ||
| The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations : distinct metabolic effects of two fat compartments. | Q51543925 | ||
| Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. | Q51574619 | ||
| PPARγ Activation Primes Human Monocytes into Alternative M2 Macrophages with Anti-inflammatory Properties | Q57244208 | ||
| A diet high in α-linolenic acid and monounsaturated fatty acids attenuates hepatic steatosis and alters hepatic phospholipid fatty acid profile in diet-induced obese rats | Q62563606 | ||
| Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study | Q71173357 | ||
| Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats | Q74348132 | ||
| Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation | Q34744890 | ||
| Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials | Q34781949 | ||
| Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial | Q35681885 | ||
| Innate immunity in the liver | Q36036373 | ||
| Statins and hepatotoxicity: focus on patients with fatty liver | Q36079406 | ||
| Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis | Q36168809 | ||
| Efficacy of MK615 for the treatment of patients with liver disorders | Q36175038 | ||
| Progression of chronic liver inflammation and fibrosis driven by activation of c-JUN signaling in Sirt6 mutant mice | Q36451932 | ||
| Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis | Q36557194 | ||
| Lipoprotein metabolism in nonalcoholic fatty liver disease | Q36682138 | ||
| SREBP-1c and TFE3, energy transcription factors that regulate hepatic insulin signaling | Q36728656 | ||
| Reduced adipose tissue macrophage content is associated with improved insulin sensitivity in thiazolidinedione-treated diabetic humans | Q36867487 | ||
| Biochemistry of oxidative stress | Q36979661 | ||
| Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment | Q37051418 | ||
| Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss | Q37105351 | ||
| Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations | Q37228756 | ||
| Metabolic disturbances in non-alcoholic fatty liver disease. | Q37401367 | ||
| Cilostazol inhibits insulin-stimulated expression of sterol regulatory binding protein-1c via inhibition of LXR and Sp1 | Q37541351 | ||
| Pioglitazone: side effect and safety profile | Q37696508 | ||
| Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection | Q37739949 | ||
| Endoplasmic Reticulum Stress and Inflammation in Obesity and Diabetes | Q37784942 | ||
| Alternative Macrophage Activation and Metabolism | Q37804862 | ||
| Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis | Q37953770 | ||
| Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment | Q38020699 | ||
| Mitochondrial dysfunction in non-alcoholic fatty liver disease and insulin resistance: cause or consequence? | Q38126549 | ||
| Potential treatment of human nonalcoholic fatty liver disease with long-chain omega-3 polyunsaturated fatty acids. | Q38154668 | ||
| Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis | Q38308819 | ||
| Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates | Q38316076 | ||
| Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease | Q38358419 | ||
| The hypolipidemic effect of cilostazol can be mediated by regulation of hepatic low-density lipoprotein receptor-related protein 1 (LRP1) expression. | Q38445993 | ||
| Dietary Monounsaturated Fatty Acids but not Saturated Fatty Acids Preserve the Insulin Signaling Pathway via IRS‐1/PI3K in Rat Skeletal Muscle | Q38480508 | ||
| Up-regulation of hepatic low-density lipoprotein receptor-related protein 1: a possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl-coenzyme A reductase inhibitor Atorvastatin and hepatic LRP1 expression. | Q38480622 | ||
| Fat redistribution preferentially reflects the anti-inflammatory benefits of pioglitazone treatment. | Q38489233 | ||
| Importance of experimental conditions in evaluating the malonyl-CoA sensitivity of liver carnitine acyltransferase. Studies with fed and starved rats | Q38576885 | ||
| P433 | issue | 11 | |
| P921 | main subject | liver disease | Q929737 |
| metabolic dysfunction–associated steatotic liver disease | Q1546498 | ||
| fatty liver disease | Q6058862 | ||
| non-alcoholic fatty liver | Q66299798 | ||
| P304 | page(s) | 800-811 | |
| P577 | publication date | 2014-11-01 | |
| P1433 | published in | World Journal of Hepatology | Q27723328 |
| P1476 | title | Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease | |
| P478 | volume | 6 |
| Q26744488 | A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence |
| Q92391926 | Alisol A attenuates high-fat-diet-induced obesity and metabolic disorders via the AMPK/ACC/SREBP-1c pathway |
| Q36764959 | Association between betatrophin/ANGPTL8 and non-alcoholic fatty liver disease: animal and human studies |
| Q39067616 | Autophagy in the liver: functions in health and disease |
| Q37239135 | Cathelicidin suppresses lipid accumulation and hepatic steatosis by inhibition of the CD36 receptor |
| Q38925531 | Endoplasmic reticulum proteostasis in hepatic steatosis. |
| Q36411266 | Genetic analysis of nonalcoholic fatty liver disease within a Caribbean-Hispanic population |
| Q48363625 | Hepatoprotective effect of parthenolide in rat model of nonalcoholic fatty liver disease |
| Q36531596 | In Situ Evaluation of Oxidative Stress in Rat Fatty Liver Induced by a Methionine- and Choline-Deficient Diet |
| Q40959440 | Increased risk for development of coronary artery calcification in subjects with non-alcoholic fatty liver disease and systemic inflammation |
| Q35670195 | Intestinal mucosal barrier dysfunction participates in the progress of nonalcoholic fatty liver disease |
| Q59607808 | Isocaloric high-fat feeding directs hepatic metabolism to handling of nutrient imbalance promoting liver fat deposition |
| Q39007563 | MAPK inhibitors modulate Smad2/3/4 complex cyto-nuclear translocation in myofibroblasts via Imp7/8 mediation. |
| Q91782011 | MiR-455 targeting SOCS3 improve liver lipid disorders in diabetic mice |
| Q47850205 | Microscopy-based high-throughput assays enable multi-parametric analysis to assess adverse effects of nanomaterials in various cell lines |
| Q64115661 | Molecular functions and clinical impact of thyroid hormone-triggered autophagy in liver-related diseases |
| Q42674175 | Nogo-B receptor deficiency increases liver X receptor alpha nuclear translocation and hepatic lipogenesis through an adenosine monophosphate-activated protein kinase alpha-dependent pathway |
| Q26746521 | Nonalcoholic Lipid Accumulation and Hepatocyte Malignant Transformation |
| Q57454669 | Nonalcoholic fatty liver disease is associated with increased hemoconcentration, thrombocytopenia, and longer hospital stay in dengue-infected patients with plasma leakage |
| Q37134761 | Nutritional Strategies for the Individualized Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) Based on the Nutrient-Induced Insulin Output Ratio (NIOR). |
| Q64978042 | PCAF fine-tunes hepatic metabolic syndrome, inflammatory disease, and cancer. |
| Q35928495 | Pathogenesis of nonalcoholic steatohepatitis |
| Q91945047 | Preventive Effect of Fermented Chestnut Inner Shell Extract on Obesity-Induced Hepatic Steatosis |
| Q37723991 | Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia |
| Q92743564 | Ramadan fasting improves liver function and total cholesterol in patients with nonalcoholic fatty liver disease |
| Q35819589 | Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome |
| Q47139930 | Reversible severe fatty liver induced by capecitabine: A case report |
| Q92604714 | Role and effective therapeutic target of gut microbiota in NAFLD/NASH |
| Q64938925 | Saturated Fatty Acid-Enriched Diet-Impaired Mitochondrial Bioenergetics in Liver From Undernourished Rats During Critical Periods of Development. |
| Q27008277 | The Global Nonalcoholic Fatty Liver Disease Epidemic: What a Radiologist Needs to Know |
| Q97537350 | The emerging role of ferroptosis in non-cancer liver diseases: hype or increasing hope? |
| Q33831012 | The imbalance of Th17/Treg cells is involved in the progression of nonalcoholic fatty liver disease in mice |
| Q36504308 | miR-212 downregulation contributes to the protective effect of exercise against non-alcoholic fatty liver via targeting FGF-21. |
Search more.